PD-L1 and CTLA-4 — Drug Target

All drugs that target PD-L1 and CTLA-4 — marketed and clinical-stage. Includes 2 drug classes acting on this target.

Drug classes

Dual checkpoint inhibitor combination (PD-L1 inhibitor + CTLA-4 inhibitor) · Dual checkpoint inhibitor (PD-L1 inhibitor + CTLA-4 inhibitor)

Phase 3 pipeline (2)

• Durvalumab +Tremelimumab · AstraZeneca · Dual checkpoint inhibitor combination (PD-L1 inhibitor + CTLA-4 inhibitor) · Oncology
  Durvalumab and tremelimumab together block PD-L1 and CTLA-4 checkpoints to unleash dual immune activation against cancer cells.
• MEDI4736 + Tremelimumab · AstraZeneca · Dual checkpoint inhibitor (PD-L1 inhibitor + CTLA-4 inhibitor) · Oncology
  MEDI4736 (durvalumab) blocks PD-L1 to restore anti-tumor immunity, while tremelimumab blocks CTLA-4 to enhance T-cell activation, together providing dual checkpoint inhibition.